Literature DB >> 1701276

Thrombotic thrombocytopenic purpura treated with high-dose intravenous gamma globulin.

M R Heyman1, T Sweet.   

Abstract

Plasma infusion and/or plasma exchange has become standard therapy in the treatment of thrombotic thrombocytopenic purpura (TTP). The management of patients in whom such primary therapy fails is difficult and uncertain. We have described a patient who obtained a sustained remission with the use of high-dose IV gamma globulin after an initial response to aggressive plasma exchange was followed by prompt relapse. Our case and others suggest that high-dose IV IgG may induce remission in patients with TTP who do not respond to standard plasma infusion and/or exchange.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1701276     DOI: 10.1097/00007611-199012000-00025

Source DB:  PubMed          Journal:  South Med J        ISSN: 0038-4348            Impact factor:   0.954


  4 in total

1.  Intravenous gamma globulin for thrombotic microangiopathy of unknown etiology.

Authors:  Shuichi Ito; Kenichi Okuyama; Tomoko Nakamura; Jun-Ichi Tetanishi; Kazuo Saito; Masanori Matsumoto; Yoshihiro Fujimura; Yukoh Aihara; Shumpei Yokota
Journal:  Pediatr Nephrol       Date:  2006-10-21       Impact factor: 3.714

Review 2.  The thrombocytopenic purpuras. Recognition and management.

Authors:  S Gillis
Journal:  Drugs       Date:  1996-06       Impact factor: 9.546

3.  Successful split liver-kidney transplant for factor H associated hemolytic uremic syndrome.

Authors:  Jeffrey M Saland; Benjamin L Shneider; Jonathan S Bromberg; Patricia A Shi; Stephen C Ward; Margret S Magid; Corinne Benchimol; Mouin G Seikaly; Sukru H Emre; Elena Bresin; Giuseppe Remuzzi
Journal:  Clin J Am Soc Nephrol       Date:  2008-11-12       Impact factor: 8.237

4.  Acquired idiopathic thrombotic thrombocytopenic purpura successfully treated with intravenous immunoglobulin and glucocorticoid: A case report.

Authors:  Hiro Nakao; Akira Ishiguro; Nahoko Ikoma; Kentaro Nishi; Chemin Su; Hisaya Nakadate; Mitsuru Kubota; Masaki Hayakawa; Masanori Matsumoto
Journal:  Medicine (Baltimore)       Date:  2017-04       Impact factor: 1.889

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.